These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 10651723)

  • 1. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
    Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
    Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells.
    Michieli M; Damiani D; Ermacora A; Raspadori D; Michelutti A; Grimaz S; Fanin R; Russo D; Lauria F; Masolini P; Baccarani M
    Br J Haematol; 1997 Feb; 96(2):356-65. PubMed ID: 9029025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
    Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
    Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia.
    Damiani D; Michelutti A; Michieli M; Masolini P; Stocchi R; Geromin A; Ermacora A; Russo D; Fanin R; Baccarani M
    Br J Haematol; 2002 Mar; 116(3):519-27. PubMed ID: 11849207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
    Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M
    Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
    Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
    Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
    Leith CP; Kopecky KJ; Chen IM; Eijdems L; Slovak ML; McConnell TS; Head DR; Weick J; Grever MR; Appelbaum FR; Willman CL
    Blood; 1999 Aug; 94(3):1086-99. PubMed ID: 10419902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
    Damiani D; Michieli M; Ermacora A; Candoni A; Raspadori D; Geromin A; Stocchi R; Grimaz S; Masolini P; Michelutti A; Scheper RJ; Baccarani M
    Haematologica; 1998 Apr; 83(4):290-7. PubMed ID: 9592977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.
    Borg AG; Burgess R; Green LM; Scheper RJ; Yin JA
    Br J Haematol; 1998 Dec; 103(4):1083-91. PubMed ID: 9886324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
    den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
    Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mechanisms of drug resistance in leukemia.
    Ross DD
    Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia.
    Ferrao P; Sincock P; Cole S; Ashman L
    Leuk Res; 2001 May; 25(5):395-405. PubMed ID: 11301107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
    Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
    Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
    Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.